Items Tagged ‘imbruvica’

July 11th, 2016

Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia

By

Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Chronic lymphocytic leukemia is the most common form of adult leukemia. The American […]

View full entry

Tags: 2016, asco, Bruton’s tyrosine kinase, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, CLL, early-stage, ibrutinib, imbruvica, Leukemia, News


March 23rd, 2016

FDA Approves Imbruvica for First Line Treatment of Chronic Lymphocytic Leukemia

By

Learn more about other FDA Approvals for CLL here. Find more information on CLL here. The US Food and Drug Administration (FDA) approved Imbruvica® (ibrutinib) for first-line use in patients with chronic lymphocytic leukemia (CLL). The approval means that there is, for the first time, a chemotherapy-free option for initial treatment of CLL.1 Chronic lymphocytic […]

View full entry

Tags: chemotherapy-free option, Chronic Lymphocytic Leukemia, CLL, first-line use, ibrutinib, imbruvica, Leukemia, News


February 24th, 2015

FDA Approves New Indication for Ibrutinib in Waldenström’s Macroglobulinemia

By

The US Food and Drug Administration (FDA) today expanded the approved use of Imbruvica® (ibrutinib) for patients with Waldenström’s macroglobulinemia, a rare type of B-cell lymphoma. Imbruvica® is the first therapy indicated specifically for Waldenström’s macroglobulinemia and previously received Breakthrough Therapy designation for this use. A type of non-Hodgkin lymphoma, Waldenström’s macroglobulinemia usually gets worse […]

View full entry

Tags: b-cell lymphoma, Breakthrough Therapy, ibrutinib, imbruvica, Indolent/Low Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, Waldenström’s macroglobulinemia


December 10th, 2014

Imbruvica® Demonstrates Clinical Activity in Relapsed or Refractory Multiple Myeloma

By

According to new data reported at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, Imbruvica® (ibrutinib) demonstrated activity in the treatment of patients with relapsed or relapsed/refractory multiple myeloma. Multiple myeloma is a cancer of plasma cells. Plasma cells are a special type of white blood cell that are part of the […]

View full entry

Tags: imbruvica, Multiple Myeloma, News, Recurrent Multiple Myeloma


September 10th, 2014

Promising Activity of Imbruvica Plus Rituxan in High-Risk CLL

By

Researchers from MD Anderson Cancer Center recently reported in the journal The Lancet Oncology that the combination of Imbruvica® (ibrutinib) and Rituxan® (rituximab) showed promising activity in the management of patients with high-risk chronic lymphocytic leukemia (CLL). CLL is characterized by the production of atypical lymphocytes. Lymphocytes are specialized immune cells that exist in two forms: B- and […]

View full entry

Tags: Chronic Lymphocytic Leukemia, CLL, ibrutinib, imbruvica, Leukemia, News


June 19th, 2014

Imbruvica Found to Extend Survival in CLL Patients

By

Researchers reported at the annual American Society of Clinical Oncology meeting in Chicago that chronic lymphoid leukemia (CLL) patients treated with Imbruvica™ (ibrutinib) showed improved survival when compared to those treated with Arzerra® (ofatumumab). Because the Imbruvica group showed a significant advantage in progression-free survival at an interim point, the trial was halted and Arzerra […]

View full entry

Tags: arzerra, asco, Chronic Lymphocytic Leukemia, CLL, ibrutinib, imbruvica, Leukemia, News